All 2005 Releases
Ligand Announces Recently Filed Shareholder Derivative Lawsuit
Oct 13, 2005
|
Ligand Announces SEC Investigation
Sep 12, 2005
|
Ligand Pharmaceuticals Requests Filing Extension from NASDAQ And Is Awaiting A Response
Sep 1, 2005
|
Ligand Pharmaceuticals Receives Staff Determination Letter from NASDAQ Regarding Delay in Filing Second Quarter Form 10-Q
Aug 23, 2005
|
Ligand Pharmaceuticals Receives Additional Filing Extension from NASDAQ
Aug 15, 2005
|
Ligand Pharmaceuticals Requests Additional Filing Extension from NASDAQ And Is Awaiting A Response
Aug 1, 2005
|
Ligand Pharmaceuticals Receives FDA Request for AVINZA(R) Label Changes to Strengthen Warnings About Alcohol Consumption While Using AVINZA
Jul 19, 2005
|
Investigators Present Results of New Lung Cancer Research with Ligand Therapies at ASCO
May 17, 2005
|
Investigators Present Detailed Targretin(R) Lung Cancer Data from SPIRIT I & II Trials at ASCO
May 16, 2005
|
Ligand Exercises Final Option to Buy Down ONTAK(R) Royalties
Apr 7, 2005
|
Ligand Earns $1.5 Million Milestone Payment as TAP Files IND for LGD2941
Apr 4, 2005
|
Investigators Present Initial Results of Two AVINZA(R) Trials at APS
Mar 30, 2005
|
Ligand Announces Conference Call
Mar 29, 2005
|
Targretin(R) Fails to Meet Primary or Secondary Endpoints in Pivotal Trials for Front-Line Non-Small Cell Lung Cancer
Mar 28, 2005
|
Ligand Announces Conference Call
Mar 28, 2005
|
Ligand Announces Conference Call
Mar 16, 2005
|
Ligand Presentation at BIO's CEO and Investor Conference to be Web Cast February 23
Feb 18, 2005
|
Ligand Earns $1.0 Million Milestone Payment as GlaxoSmithKline Commences Phase II Studies of Oral Drug for Thrombocytopenia
Feb 7, 2005
|
Pfizer Submits SNDA to Expand Potential Market for Lasofoxifene; Triggers Ligand Royalty Buy-Out Option from Salk and Expands Potential Ligand Royalty Revenue
Feb 3, 2005
|
Ligand Exercises First Option to Buy Down ONTAK(R) Royalties
Jan 7, 2005
|
| Showing 1-20 of 20 |
Page: 1 |
|
|
